Meros Investment Management LP purchased a new stake in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 170,000 shares of the medical device company’s stock, valued at approximately $4,756,600,000. Meros Investment Management LP owned 0.33% of AtriCure at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure during the 2nd quarter worth about $37,000. Smartleaf Asset Management LLC increased its position in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares during the period. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure during the second quarter worth approximately $40,000. Allworth Financial LP acquired a new position in shares of AtriCure during the second quarter worth approximately $43,000. Finally, Fifth Third Bancorp bought a new stake in shares of AtriCure in the first quarter valued at approximately $51,000. 99.11% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, Director Maggie Yuen sold 3,500 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the sale, the director owned 14,015 shares of the company’s stock, valued at approximately $538,456.30. This represents a 19.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sven Wehrwein sold 25,000 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the sale, the director owned 40,518 shares of the company’s stock, valued at $1,533,201.12. This trade represents a 38.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 44,246 shares of company stock worth $1,691,895 in the last three months. Company insiders own 4.00% of the company’s stock.
AtriCure Price Performance
AtriCure (NASDAQ:ATRC – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same period in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, sell-side analysts forecast that AtriCure, Inc. will post 0.2 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms recently commented on ATRC. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. BTIG Research boosted their price objective on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday. UBS Group cut their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Canaccord Genuity Group lifted their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $48.62.
Check Out Our Latest Research Report on ATRC
AtriCure Company Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
- Five stocks we like better than AtriCure
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
